BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27999621)

  • 1. Promoter hypermethylation of
    Branchi V; Schaefer P; Semaan A; Kania A; Lingohr P; Kalff JC; Schäfer N; Kristiansen G; Dietrich D; Matthaei H
    Clin Epigenetics; 2016; 8():133. PubMed ID: 27999621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.
    de Vos L; Gevensleben H; Schröck A; Franzen A; Kristiansen G; Bootz F; Dietrich D
    Clin Epigenetics; 2017; 9():125. PubMed ID: 29213339
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Semaan A; van Ellen A; Meller S; Bergheim D; Branchi V; Lingohr P; Goltz D; Kalff JC; Kristiansen G; Matthaei H; Pantelis D; Dietrich D
    Clin Epigenetics; 2016; 8():100. PubMed ID: 27660666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
    Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
    Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions.
    Dietrich D; Jung M; Puetzer S; Leisse A; Holmes EE; Meller S; Uhl B; Schatz P; Ivascu C; Kristiansen G
    PLoS One; 2013; 8(12):e84225. PubMed ID: 24386354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood: An Observational Prospective Study.
    de Vos L; Jung M; Koerber RM; Bawden EG; Holderried TAW; Dietrich J; Bootz F; Brossart P; Kristiansen G; Dietrich D
    J Mol Diagn; 2020 Jul; 22(7):920-933. PubMed ID: 32361006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.
    Uhl B; Dietrich D; Branchi V; Semaan A; Schaefer P; Gevensleben H; Rostamzadeh B; Lingohr P; Schäfer N; Kalff JC; Kristiansen G; Matthaei H
    PLoS One; 2016; 11(10):e0165769. PubMed ID: 27798672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
    Jung M; Pützer S; Gevensleben H; Meller S; Kristiansen G; Dietrich D
    Clin Epigenetics; 2016; 8():24. PubMed ID: 26937257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.
    Schröck A; Leisse A; de Vos L; Gevensleben H; Dröge F; Franzen A; Wachendörfer M; Schröck F; Ellinger J; Teschke M; Wilhelm-Buchstab T; Landsberg J; Holdenrieder S; Hartmann G; Field JK; Bootz F; Kristiansen G; Dietrich D
    Clin Chem; 2017 Jul; 63(7):1288-1296. PubMed ID: 28515105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
    Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
    J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Diagnosis Method Based on Methylation Analysis of SHOX2 and Serum Biomarker for Early Stage Lung Cancer.
    Huang W; Huang H; Zhang S; Wang X; Ouyang J; Lin Z; Chen P
    Cancer Control; 2020; 27(1):1073274820969703. PubMed ID: 33167712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Dynamics of Quantitative
    Krausewitz P; Kluemper N; Richter AP; Büttner T; Kristiansen G; Ritter M; Ellinger J
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic Efficacy of SHOX2 Gene Hypermethylation for Lung Cancer: A Meta-Analysis].
    Liu Q; Wang S; Pei G; Yang Y; Huang Y
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):490-496. PubMed ID: 34275516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients.
    Tozawa T; Tamura G; Honda T; Nawata S; Kimura W; Makino N; Kawata S; Sugai T; Suto T; Motoyama T
    Cancer Sci; 2004 Sep; 95(9):736-40. PubMed ID: 15471559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation of the SEPT9_v2 promoter as a novel marker for the detection of circulating tumor DNA in breast cancer patients.
    Matsui S; Kagara N; Mishima C; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Oncol Rep; 2016 Oct; 36(4):2225-35. PubMed ID: 27499429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma.
    Kneip C; Schmidt B; Seegebarth A; Weickmann S; Fleischhacker M; Liebenberg V; Field JK; Dietrich D
    J Thorac Oncol; 2011 Oct; 6(10):1632-8. PubMed ID: 21694641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Laven-Law G; Kichenadasse G; Young GP; Symonds EL; Winter JM
    Biomarkers; 2024 Jun; 29(4):194-204. PubMed ID: 38644767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker.
    Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S
    Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter methylation of SEPT9 as a potential biomarker for early detection of cervical cancer and its overexpression predicts radioresistance.
    Jiao X; Zhang S; Jiao J; Zhang T; Qu W; Muloye GM; Kong B; Zhang Q; Cui B
    Clin Epigenetics; 2019 Aug; 11(1):120. PubMed ID: 31426855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.